CD160 and neoplasm: XCL1 or CD160 expression co-localised with LGR6 expression (Fig. 2h, Supplementary Fig. 8c), and co-expression within tumours was seen in 16.3% (16/98) of our cohort for XCL1 and LGR6, and 27.8% (25/90) for CD160 and LGR6 (Supplementary Data 6 and 7).